SCHEMBL30928372

SCHEMBL30928372

Cc1ccc(F)c(S(=O)(=O)NC(C)(C)C)n1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C9 P11712 1/20 0.40
MAPK1 P28482 1/20 0.40
HSD11B1 P28845 1/20 0.37
ALOX5AP P20292 11/20 0.37
FEN1 P39748 11/20 0.37
SMN1; SMN2 Q16637 3/20 0.37
MAPT P10636 2/20 0.37
LMNA P02545 2/20 0.37
KDM4E B2RXH2 1/20 0.37
MEN1 O00255 1/20 0.37
NPC1 O15118 1/20 0.37
HPGD P15428 1/20 0.37
RAB9A P51151 1/20 0.37
KMT2A Q03164 1/20 0.37
HTT P42858 1/20 0.34
NSD2 O96028 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8112909 0.80 ALDH1A1 (0.37) ALDH1A1CYP3A4CYP2C9MAPK1SMN1; SMN2
SCHEMBL8105849 0.79 ALDH1A1 (0.36) ALDH1A1CYP3A4CYP2C9MAPK1ALOX5AP
SCHEMBL9367060 0.74 GAA (0.43) ALDH1A1SMN1; SMN2MAPTLMNAKDM4E
SCHEMBL8114335 0.74 ALDH1A1 (0.35) ALDH1A1CYP3A4CYP2C9MAPK1SMN1; SMN2
SCHEMBL31017736 0.71 HSD11B1 (0.49) ALDH1A1HSD11B1MAPTLMNAKDM4E
SCHEMBL31017728 0.70 SCN1A (0.47) CYP2C9
SCHEMBL31017734 0.69 SCN8A (0.55) CYP2C9
SCHEMBL16377391 0.69 ALDH1A1 (0.46) ALDH1A1CYP3A4CYP2C9MAPK1ALOX5AP
SCHEMBL8112810 0.69 SLC40A1 (0.49) ALDH1A1HSD11B1SMN1; SMN2MAPTLMNA
SCHEMBL21963333 0.68 ALDH1A1 (0.37) ALDH1A1CYP3A4CYP2C9MAPK1ALOX5AP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240182460-A1 ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE PETRA PHARMA CORPORATION 2024-06-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240182460-A1 ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE PIK3CA, PIK3R4, PIK3R5 ALDH1A1 3403/4885CYP3A4 629/4885CYP2C9 822/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.